Tango Therapeutics Inc (NASDAQ: TNGX) on Friday, soared 21.37% from the previous trading day, before settling in for the closing price of $3.51. Within the past 52 weeks, TNGX’s price has moved between $1.03 and $12.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 53.11% annually for the last half of the decade. The company achieved an average annual earnings per share of -14.29%. With a float of $58.92 million, this company’s outstanding shares have now reached $108.11 million.
In an organization with 155 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 83.79%, operating margin of -355.86%, and the pretax margin is -322.17%.
Tango Therapeutics Inc (TNGX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tango Therapeutics Inc is 45.64%, while institutional ownership is 55.93%. The most recent insider transaction that took place on Feb 04 ’25, was worth 8,289. In this transaction General Counsel of this company sold 2,774 shares at a rate of $2.99, taking the stock ownership to the 68,570 shares. Before that another transaction happened on Feb 05 ’25, when Company’s General Counsel sold 2,556 for $3.16, making the entire transaction worth $8,081. This insider now owns 66,014 shares in total.
Tango Therapeutics Inc (TNGX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -14.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.61% during the next five years compared to 7.47% growth over the previous five years of trading.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Tango Therapeutics Inc (TNGX) is currently performing well based on its current performance indicators. A quick ratio of 6.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.32 in one year’s time.
Technical Analysis of Tango Therapeutics Inc (TNGX)
Let’s dig in a bit further. During the last 5-days, its volume was 6.19 million. That was better than the volume of 1.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 84.68%. Additionally, its Average True Range was 0.47.
During the past 100 days, Tango Therapeutics Inc’s (TNGX) raw stochastic average was set at 87.77%, which indicates a significant increase from 86.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 223.77% in the past 14 days, which was higher than the 131.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.69, while its 200-day Moving Average is $4.04. However, in the short run, Tango Therapeutics Inc’s stock first resistance to watch stands at $4.79. Second resistance stands at $5.31. The third major resistance level sits at $5.92. If the price goes on to break the first support level at $3.66, it is likely to go to the next support level at $3.05. Assuming the price breaks the second support level, the third support level stands at $2.53.
Tango Therapeutics Inc (NASDAQ: TNGX) Key Stats
Market capitalization of the company is 461.76 million based on 108,394K outstanding shares. Right now, sales total 42,070 K and income totals -130,300 K. The company made 5,390 K in profit during its latest quarter, and -39,880 K in sales during its previous quarter.
